rs61752479

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BP4_StrongBP6BA1

The NM_000036.3(AMPD1):​c.143C>T​(p.Pro48Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.112 in 1,613,946 control chromosomes in the GnomAD database, including 11,561 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity,other (no stars). Synonymous variant affecting the same amino acid position (i.e. P48P) has been classified as Likely benign.

Frequency

Genomes: 𝑓 0.086 ( 781 hom., cov: 32)
Exomes 𝑓: 0.11 ( 10780 hom. )

Consequence

AMPD1
NM_000036.3 missense

Scores

6
7
5

Clinical Significance

Conflicting classifications of pathogenicity; other criteria provided, conflicting classifications U:2B:5O:1

Conservation

PhyloP100: 9.35

Publications

27 publications found
Variant links:
Genes affected
AMPD1 (HGNC:468): (adenosine monophosphate deaminase 1) Adenosine monophosphate deaminase 1 catalyzes the deamination of AMP to IMP in skeletal muscle and plays an important role in the purine nucleotide cycle. Two other genes have been identified, AMPD2 and AMPD3, for the liver- and erythocyte-specific isoforms, respectively. Deficiency of the muscle-specific enzyme is apparently a common cause of exercise-induced myopathy and probably the most common cause of metabolic myopathy in the human. Alternatively spliced transcript variants encoding different isoforms have been identified in this gene.[provided by RefSeq, Feb 2010]
AMPD1 Gene-Disease associations (from GenCC):
  • myopathy due to myoadenylate deaminase deficiency
    Inheritance: AR Classification: STRONG Submitted by: Labcorp Genetics (formerly Invitae)
  • adenosine monophosphate deaminase deficiency
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.0030060112).
BP6
Variant 1-114688633-G-A is Benign according to our data. Variant chr1-114688633-G-A is described in ClinVar as Conflicting_classifications_of_pathogenicity|other. ClinVar VariationId is 50897.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.132 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
AMPD1NM_000036.3 linkc.143C>T p.Pro48Leu missense_variant Exon 3 of 16 ENST00000520113.7 NP_000027.3 P23109-1
AMPD1NM_001172626.2 linkc.131C>T p.Pro44Leu missense_variant Exon 2 of 15 NP_001166097.2 P23109-2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
AMPD1ENST00000520113.7 linkc.143C>T p.Pro48Leu missense_variant Exon 3 of 16 1 NM_000036.3 ENSP00000430075.3 P23109-1
AMPD1ENST00000369538.4 linkc.131C>T p.Pro44Leu missense_variant Exon 2 of 15 2 ENSP00000358551.4 P23109-2
AMPD1ENST00000637080.1 linkn.146C>T non_coding_transcript_exon_variant Exon 2 of 14 5 ENSP00000489753.1 A0A1B0GTL6

Frequencies

GnomAD3 genomes
AF:
0.0865
AC:
13148
AN:
152026
Hom.:
781
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0221
Gnomad AMI
AF:
0.135
Gnomad AMR
AF:
0.0727
Gnomad ASJ
AF:
0.0735
Gnomad EAS
AF:
0.000577
Gnomad SAS
AF:
0.0282
Gnomad FIN
AF:
0.119
Gnomad MID
AF:
0.0981
Gnomad NFE
AF:
0.134
Gnomad OTH
AF:
0.0839
GnomAD2 exomes
AF:
0.0876
AC:
22018
AN:
251420
AF XY:
0.0888
show subpopulations
Gnomad AFR exome
AF:
0.0202
Gnomad AMR exome
AF:
0.0509
Gnomad ASJ exome
AF:
0.0768
Gnomad EAS exome
AF:
0.0000544
Gnomad FIN exome
AF:
0.116
Gnomad NFE exome
AF:
0.132
Gnomad OTH exome
AF:
0.0932
GnomAD4 exome
AF:
0.115
AC:
167963
AN:
1461802
Hom.:
10780
Cov.:
32
AF XY:
0.113
AC XY:
82083
AN XY:
727200
show subpopulations
African (AFR)
AF:
0.0179
AC:
598
AN:
33480
American (AMR)
AF:
0.0524
AC:
2342
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
0.0794
AC:
2076
AN:
26136
East Asian (EAS)
AF:
0.000151
AC:
6
AN:
39700
South Asian (SAS)
AF:
0.0357
AC:
3079
AN:
86258
European-Finnish (FIN)
AF:
0.119
AC:
6331
AN:
53418
Middle Eastern (MID)
AF:
0.0700
AC:
404
AN:
5768
European-Non Finnish (NFE)
AF:
0.132
AC:
146903
AN:
1111922
Other (OTH)
AF:
0.103
AC:
6224
AN:
60396
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.471
Heterozygous variant carriers
0
8735
17469
26204
34938
43673
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
5040
10080
15120
20160
25200
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0864
AC:
13146
AN:
152144
Hom.:
781
Cov.:
32
AF XY:
0.0837
AC XY:
6223
AN XY:
74378
show subpopulations
African (AFR)
AF:
0.0220
AC:
915
AN:
41500
American (AMR)
AF:
0.0726
AC:
1110
AN:
15284
Ashkenazi Jewish (ASJ)
AF:
0.0735
AC:
255
AN:
3470
East Asian (EAS)
AF:
0.000578
AC:
3
AN:
5186
South Asian (SAS)
AF:
0.0278
AC:
134
AN:
4822
European-Finnish (FIN)
AF:
0.119
AC:
1258
AN:
10570
Middle Eastern (MID)
AF:
0.102
AC:
30
AN:
294
European-Non Finnish (NFE)
AF:
0.134
AC:
9144
AN:
68000
Other (OTH)
AF:
0.0825
AC:
174
AN:
2108
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
607
1215
1822
2430
3037
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
150
300
450
600
750
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.113
Hom.:
3902
Bravo
AF:
0.0799
TwinsUK
AF:
0.144
AC:
533
ALSPAC
AF:
0.127
AC:
491
ESP6500AA
AF:
0.0234
AC:
103
ESP6500EA
AF:
0.133
AC:
1144
ExAC
AF:
0.0884
AC:
10728
Asia WGS
AF:
0.0220
AC:
77
AN:
3478
EpiCase
AF:
0.125
EpiControl
AF:
0.128

ClinVar

Significance: Conflicting classifications of pathogenicity; other
Submissions summary: Uncertain:2Benign:5Other:1
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not provided Uncertain:1Benign:2Other:1
Feb 07, 2018
Eurofins Ntd Llc (ga)
Significance:other
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- Variant classified as "other reportable" ??? variant is clinically benign (not associated with disease) but is reported when observed (e.g. pseudodeficiency alleles).

Jun 09, 2021
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is associated with the following publications: (PMID: 1631143, 33250842, 21228398, 20981092) -

Jun 01, 2018
CeGaT Center for Human Genetics Tuebingen
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

-
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Muscle AMP deaminase deficiency Uncertain:1Benign:2
Jan 06, 2021
Clinical Genomics Laboratory, Stanford Medicine
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

The p.Pro81Leu variant in the AMPD1 gene has been previously reported in 11 unrelated individuals with reported AMPD deficiency (Morisaki et al., 1992). Of note, all individuals were homozygous for this variant as well as the p.Gln45* variant. The highest allele frequency of the p.Pro81Leu variant was identified in the European population at 17,214/129,128 chromosomes (13.33%) by the Genome Aggregation Database (http://gnomad.broadinstitute.org/). Computational tools predict that the p.Pro81Leu variant is deleterious; however, the accuracy of in silico algorithms is limited. These data were assessed using the ACMG/AMP variant interpretation guidelines. In summary, the significance of the p.Pro81Leu variant is uncertain. Additional information is needed to resolve the significance of this variant. [ACMG evidence codes used: PP3] -

Jan 06, 2020
Al Jalila Children’s Genomics Center, Al Jalila Childrens Speciality Hospital
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 03, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

AMPD1-related disorder Benign:1
Dec 01, 2023
PreventionGenetics, part of Exact Sciences
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.63
BayesDel_addAF
Benign
-0.23
T
BayesDel_noAF
Uncertain
0.030
CADD
Pathogenic
29
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.67
D;.
Eigen
Pathogenic
0.71
Eigen_PC
Pathogenic
0.69
FATHMM_MKL
Pathogenic
0.99
D
LIST_S2
Benign
0.83
T;T
MetaRNN
Benign
0.0030
T;T
MetaSVM
Benign
-0.43
T
MutationAssessor
Uncertain
2.4
M;.
PhyloP100
9.3
PrimateAI
Uncertain
0.58
T
PROVEAN
Pathogenic
-4.8
D;D
REVEL
Uncertain
0.51
Sift
Pathogenic
0.0
D;D
Sift4G
Uncertain
0.012
D;D
Vest4
0.32
MPC
0.46
ClinPred
0.028
T
GERP RS
5.6
Varity_R
0.66
gMVP
0.69
Mutation Taster
=92/8
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs61752479; hg19: chr1-115231254; COSMIC: COSV62415390; COSMIC: COSV62415390; API